Telesis Bio Inc (TBIO) shares skyrocketed in extended trading on Wednesday following the announcement of a groundbreaking partnership aimed at revolutionizing DNA and mRNA synthesis. The company has joined forces with Beckman Coulter Life Sciences, a leader in laboratory automation and innovation, to establish efficient and scalable biofoundries that deliver cutting-edge solutions for DNA synthesis.
This strategic alliance will seamlessly integrate Telesis Bio’s renowned Gibson SOLA Enzymatic Synthesis technology with Beckman Coulter’s state-of-the-art Biomek Echo One System. This integration will significantly enhance the flexibility and capabilities of biofoundries, enabling them to synthesize biological materials with unprecedented efficiency.
Eric Esser, the CEO of Telesis Bio, highlighted the significance of this collaboration, stating, “This partnership marks a significant milestone in advancing synthetic biology. By integrating Gibson SOLA’s high-fidelity, scalable, and non-toxic DNA synthesis capabilities with Beckman Coulter Life Sciences automation expertise, we are setting a new standard for on-premises biofoundries.” He further emphasized the transformative impact on researchers, stating, “This collaboration empowers researchers to greatly improve productivity through faster, more reliable and innovative solutions, driving forward the next generation of therapeutic and diagnostic advancements.”
Telesis Bio is renowned for its non-toxic, high-fidelity, and scalable DNA synthesis solutions, empowering scientists to develop novel, synthetic biology-enabled solutions. The company is categorized as a low-float stock, with approximately 406,000 shares readily available for public trading. Its market cap, as of Wednesday’s close, was less than $5 million. Low-float, micro-cap stocks are often associated with elevated volatility, potentially contributing to the significant post-market surge in Telesis Bio’s share price.
In after-hours trading on Wednesday, TBIO shares soared by an astonishing 110.02%, closing at $4.87, according to Benzinga Pro. This partnership marks a significant step forward in the field of synthetic biology, promising to accelerate the development of innovative therapeutic and diagnostic solutions.
